Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,1-dichloroethene | increases expression | EXP | | 6480464 | vinylidene chloride results in increased expression of LRIG1 mRNA | CTD | PMID:26682919 | 1,2-dichloroethane | increases expression | EXP | | 6480464 | ethylene dichloride results in increased expression of LRIG1 mRNA | CTD | PMID:28960355 | 1,2-dimethylhydrazine | multiple interactions | EXP | | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of LRIG1 mRNA | CTD | PMID:22206623 | 1,2-dimethylhydrazine | decreases expression | EXP | | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of LRIG1 mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | multiple interactions | EXP | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of LRIG1 mRNA | CTD | PMID:17942748 | 17beta-estradiol | multiple interactions | ISO | RGD:1315602 | 6480464 | [Estradiol co-treated with TGFB1 protein] results in decreased expression of LRIG1 mRNA | CTD | PMID:30165855 | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | ISO | RGD:1315602 | 6480464 | Dihydrotestosterone results in increased expression of LRIG1 mRNA | CTD | PMID:29581250 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | EXP | | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of LRIG1 mRNA more ... | CTD | PMID:17942748, PMID:28973660 | 2,3,7,8-tetrachlorodibenzodioxine | increases response to substance | EXP | | 6480464 | LRIG1 results in increased susceptibility to Tetrachlorodibenzodioxin | CTD | PMID:28973660 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of LRIG1 mRNA | CTD | PMID:26290441 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1315602 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of LRIG1 mRNA | CTD | PMID:20106945 more ... | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of LRIG1 mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of LRIG1 mRNA | CTD | PMID:18691609 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1315602 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of LRIG1 mRNA | CTD | PMID:28628672 | 4,4'-diaminodiphenylmethane | increases expression | EXP | | 6480464 | 4, 4'-diaminodiphenylmethane results in increased expression of LRIG1 mRNA | CTD | PMID:18648102 | 4-hydroxyphenyl retinamide | decreases expression | EXP | | 6480464 | Fenretinide results in decreased expression of LRIG1 mRNA | CTD | PMID:28973697 | 6-propyl-2-thiouracil | decreases expression | ISO | RGD:1306788 | 6480464 | Propylthiouracil results in decreased expression of LRIG1 mRNA | CTD | PMID:24780913 | aflatoxin B1 | decreases expression | ISO | RGD:1315602 | 6480464 | Aflatoxin B1 results in decreased expression of LRIG1 mRNA | CTD | PMID:21641981 | aflatoxin B1 | decreases methylation | ISO | RGD:1315602 | 6480464 | Aflatoxin B1 results in decreased methylation of LRIG1 gene | CTD | PMID:27153756 | all-trans-retinoic acid | decreases expression | ISO | RGD:1315602 | 6480464 | Tretinoin results in decreased expression of LRIG1 mRNA | CTD | PMID:21934132 | amphetamine | decreases expression | ISO | RGD:1306788 | 6480464 | Amphetamine results in decreased expression of LRIG1 mRNA | CTD | PMID:30779732 | arsane | affects expression | ISO | RGD:1315602 | 6480464 | Arsenic affects the expression of LRIG1 mRNA | CTD | PMID:18414638 | arsenic atom | affects expression | ISO | RGD:1315602 | 6480464 | Arsenic affects the expression of LRIG1 mRNA | CTD | PMID:18414638 | benzo[a]pyrene | decreases expression | ISO | RGD:1315602 | 6480464 | Benzoapyrene results in decreased expression of LRIG1 mRNA | CTD | PMID:22316170, PMID:26238291 | benzo[a]pyrene | affects methylation | ISO | RGD:1315602 | 6480464 | Benzoapyrene affects the methylation of LRIG1 intron | CTD | PMID:30157460 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RGD:1315602 | 6480464 | 7 more ... | CTD | PMID:20382639 | benzo[e]pyrene | increases methylation | ISO | RGD:1315602 | 6480464 | benzoepyrene results in increased methylation of LRIG1 intron | CTD | PMID:30157460 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | RGD:1315602 | 6480464 | Diethylhexyl Phthalate results in decreased expression of LRIG1 mRNA | CTD | PMID:31163220 | bisphenol F | multiple interactions | ISO | RGD:1315602 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of LRIG1 mRNA | CTD | PMID:28628672 | calcitriol | increases expression | ISO | RGD:1315602 | 6480464 | Calcitriol results in increased expression of LRIG1 mRNA | CTD | PMID:21592394 | calcitriol | multiple interactions | ISO | RGD:1315602 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of LRIG1 mRNA | CTD | PMID:21592394 | carbon nanotube | increases expression | EXP | | 6480464 | Nanotubes more ... | CTD | PMID:25620056 | carbon nanotube | decreases expression | EXP | | 6480464 | Nanotubes, Carbon results in decreased expression of LRIG1 mRNA | CTD | PMID:25554681 | ciguatoxin CTX1B | affects expression | EXP | | 6480464 | Ciguatoxins affects the expression of LRIG1 mRNA | CTD | PMID:18353800 | cisplatin | multiple interactions | ISO | RGD:1315602 | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of LRIG1 mRNA, LRIG1 protein inhibits the reaction [Cisplatin results in increased phosphorylation of and affects the localization of EGFR protein] | CTD | PMID:21431282, PMID:27392435 | cisplatin | decreases expression | ISO | RGD:1315602 | 6480464 | Cisplatin results in decreased expression of LRIG1 mRNA | CTD | PMID:27392435 | cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of LRIG1 mRNA | CTD | PMID:21151649 | cisplatin | increases response to substance | ISO | RGD:1315602 | 6480464 | LRIG1 protein results in increased susceptibility to Cisplatin | CTD | PMID:21431282 | clothianidin | increases expression | ISO | RGD:1315602 | 6480464 | clothianidin results in increased expression of LRIG1 mRNA | CTD | PMID:31626844 | copper(II) sulfate | decreases expression | ISO | RGD:1315602 | 6480464 | Copper Sulfate results in decreased expression of LRIG1 mRNA | CTD | PMID:19549813 | coumestrol | multiple interactions | ISO | RGD:1315602 | 6480464 | [Coumestrol co-treated with 2 more ... | CTD | PMID:19167446 | crocidolite asbestos | decreases expression | ISO | RGD:1315602 | 6480464 | Asbestos, Crocidolite results in decreased expression of LRIG1 mRNA | CTD | PMID:29523930 | cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of LRIG1 mRNA | CTD | PMID:19770486 | cyclosporin A | decreases expression | ISO | RGD:1315602 | 6480464 | Cyclosporine results in decreased expression of LRIG1 mRNA | CTD | PMID:25562108 | cytarabine | increases expression | ISO | RGD:1315602 | 6480464 | Cytarabine results in increased expression of LRIG1 mRNA | CTD | PMID:21198554 | dexamethasone | decreases expression | EXP | | 6480464 | Dexamethasone results in decreased expression of LRIG1 mRNA | CTD | PMID:22733784 | dexamethasone | multiple interactions | ISO | RGD:1315602 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of LRIG1 mRNA | CTD | PMID:28628672 | dioxygen | increases expression | EXP | | 6480464 | Oxygen deficiency results in increased expression of LRIG1 mRNA | CTD | PMID:24205000 | dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate | decreases expression | ISO | RGD:1315602 | 6480464 | Antimony Potassium Tartrate results in decreased expression of LRIG1 mRNA | CTD | PMID:28713220 | dorsomorphin | multiple interactions | ISO | RGD:1315602 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... | CTD | PMID:27188386 | Enterolactone | multiple interactions | ISO | RGD:1315602 | 6480464 | [Coumestrol co-treated with 2, 3-bis3'-hydroxybenzylbutyrolactone] results in increased expression of LRIG1 mRNA | CTD | PMID:19167446 | ethanol | increases expression | EXP | | 6480464 | Ethanol results in increased expression of LRIG1 mRNA | CTD | PMID:30319688 | ethyl methanesulfonate | decreases expression | ISO | RGD:1315602 | 6480464 | Ethyl Methanesulfonate results in decreased expression of LRIG1 mRNA | CTD | PMID:23649840 | fluoranthene | multiple interactions | EXP | | 6480464 | [1-methylanthracene co-treated with fluoranthene] results in increased expression of LRIG1 mRNA | CTD | PMID:28329830 | folic acid | multiple interactions | EXP | | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of LRIG1 mRNA | CTD | PMID:22206623 | indometacin | multiple interactions | ISO | RGD:1315602 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of LRIG1 mRNA | CTD | PMID:28628672 | lead diacetate | decreases expression | EXP | | 6480464 | lead acetate results in decreased expression of LRIG1 mRNA | CTD | PMID:22613225 | lead(0) | affects expression | ISO | RGD:1315602 | 6480464 | Lead affects the expression of LRIG1 mRNA | CTD | PMID:28903495 | lead(2+) | affects expression | ISO | RGD:1315602 | 6480464 | Lead affects the expression of LRIG1 mRNA | CTD | PMID:28903495 | menadione | affects expression | ISO | RGD:1315602 | 6480464 | Vitamin K 3 affects the expression of LRIG1 mRNA | CTD | PMID:20044591 | methapyrilene | increases methylation | ISO | RGD:1315602 | 6480464 | Methapyrilene results in increased methylation of LRIG1 intron | CTD | PMID:30157460 | methyl methanesulfonate | decreases expression | ISO | RGD:1315602 | 6480464 | Methyl Methanesulfonate results in decreased expression of LRIG1 mRNA | CTD | PMID:23649840 | mono(2-ethylhexyl) phthalate | affects expression | EXP | | 6480464 | mono-2-ethylhexylphthalate affects the expression of LRIG1 mRNA | CTD | PMID:21195148 | Monobutylphthalate | affects expression | EXP | | 6480464 | monobutyl phthalate affects the expression of LRIG1 mRNA | CTD | PMID:21195148 | N-methyl-4-phenylpyridinium | increases expression | ISO | RGD:1315602 | 6480464 | 1-Methyl-4-phenylpyridinium results in increased expression of LRIG1 mRNA | CTD | PMID:24810058 | panobinostat | decreases expression | ISO | RGD:1315602 | 6480464 | panobinostat results in decreased expression of LRIG1 mRNA | CTD | PMID:26272509 | panobinostat | multiple interactions | ISO | RGD:1315602 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of LRIG1 mRNA | CTD | PMID:27188386 | phenylmercury acetate | decreases expression | ISO | RGD:1315602 | 6480464 | Phenylmercuric Acetate results in decreased expression of LRIG1 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | RGD:1315602 | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of LRIG1 mRNA | CTD | PMID:27188386 | pirinixic acid | decreases expression | EXP | | 6480464 | pirinixic acid results in decreased expression of LRIG1 mRNA | CTD | PMID:18445702 more ... | progesterone | increases expression | ISO | RGD:1315602 | 6480464 | Progesterone results in increased expression of LRIG1 mRNA | CTD | PMID:20864642 | quercetin | decreases expression | ISO | RGD:1315602 | 6480464 | Quercetin results in decreased expression of LRIG1 mRNA | CTD | PMID:21632981 | raloxifene | multiple interactions | ISO | RGD:1315602 | 6480464 | [Raloxifene Hydrochloride co-treated with ESR2 protein] results in decreased expression of LRIG1 mRNA | CTD | PMID:19059307 | raloxifene | affects expression | ISO | RGD:1315602 | 6480464 | Raloxifene Hydrochloride affects the expression of LRIG1 mRNA | CTD | PMID:14699072 | resveratrol | multiple interactions | ISO | RGD:1315602 | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of LRIG1 mRNA | CTD | PMID:19167446 | SB 431542 | multiple interactions | ISO | RGD:1315602 | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... | CTD | PMID:27188386 | silicon dioxide | decreases expression | ISO | RGD:1315602 | 6480464 | Silicon Dioxide analog results in decreased expression of LRIG1 mRNA | CTD | PMID:25895662 | sodium arsenite | decreases expression | ISO | RGD:1315602 | 6480464 | sodium arsenite results in decreased expression of LRIG1 mRNA | CTD | PMID:28713220 | sulforaphane | increases expression | ISO | RGD:1315602 | 6480464 | sulforafan results in increased expression of LRIG1 mRNA | CTD | PMID:31838189 | sunitinib | decreases expression | ISO | RGD:1315602 | 6480464 | Sunitinib results in decreased expression of LRIG1 mRNA | CTD | PMID:31533062 | tamoxifen | multiple interactions | ISO | RGD:1315602 | 6480464 | [Tamoxifen co-treated with ESR2 protein] results in decreased expression of LRIG1 mRNA | CTD | PMID:19059307 | tamoxifen | affects expression | ISO | RGD:1315602 | 6480464 | Tamoxifen affects the expression of LRIG1 mRNA | CTD | PMID:14699072 | testosterone | multiple interactions | ISO | RGD:1315602 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of LRIG1 mRNA | CTD | PMID:21592394 | testosterone | increases expression | ISO | RGD:1315602 | 6480464 | Testosterone results in increased expression of LRIG1 mRNA | CTD | PMID:21592394 | tetrachloromethane | increases expression | EXP | | 6480464 | Carbon Tetrachloride results in increased expression of LRIG1 mRNA | CTD | PMID:31919559 | trichostatin A | decreases expression | ISO | RGD:1315602 | 6480464 | trichostatin A results in decreased expression of LRIG1 mRNA | CTD | PMID:24935251, PMID:26272509 | trichostatin A | multiple interactions | ISO | RGD:1315602 | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of LRIG1 mRNA | CTD | PMID:27188386 | urethane | increases expression | ISO | RGD:1315602 | 6480464 | Urethane results in increased expression of LRIG1 mRNA | CTD | PMID:28818685 | valproic acid | increases expression | ISO | RGD:1315602 | 6480464 | Valproic Acid results in increased expression of LRIG1 mRNA | CTD | PMID:19101580, PMID:29154799 | valproic acid | multiple interactions | ISO | RGD:1315602 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of LRIG1 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | RGD:1315602 | 6480464 | Valproic Acid results in decreased expression of LRIG1 mRNA | CTD | PMID:23179753 more ... | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of LRIG1 mRNA | CTD | PMID:17963808 | vorinostat | decreases expression | ISO | RGD:1315602 | 6480464 | vorinostat results in decreased expression of LRIG1 mRNA | CTD | PMID:26272509 | vorinostat | multiple interactions | ISO | RGD:1315602 | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in decreased expression of LRIG1 mRNA | CTD | PMID:27188386 | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
Welcome {{ username}}
Message Center
{{ messageCount }} Messages
Watched Genes
{{$index + 1}}. {{ watchedObject.symbol }} (RGD ID:{{watchedObject.rgdId}})
Watched Ontology Terms
{{gene.symbol}}: {{ gene.description }}
|
| Save what matters to you |
| {{ loginError }} |
| Sign in with your RGD account |
| Create New Account | Recover Password |
Analyze GeneStrainQTL List |
 Gene Annotator (Functional Annotation) unavailable |
 Gene Annotator (Annotation Distribution) unavailable |
 Variant Visualizer (Genomic Variants) unavailble Variant Visualizer (Genomic Variants) unavailable |
Gene Annotator (Functional Annotation) |
Gene Annotator (Annotation Distribution) |
Variant Visualizer (Genomic Variants) |
 InterViewer (Protein-Protein Interactions) unavailable |
 Gviewer (Genome Viewer) unavailable |
 Variant Visualizer (Damaging Variants) unavailble Variant Visualizer (Damaging Variants) unavailable |
InterViewer (Protein-Protein Interactions) |
GViewer (Genome Viewer) |
Variant Visualizer (Damaging Variants) |
 Gene Annotator (Annotation Comparison) unavailable |
 OLGA (Gene List Generator) unavailable |
 |
Gene Annotator (Annotation Comparison) |
OLGA (Gene List Generator) |
Excel (Download) |
 MOET (Multi-Ontology Enrichement) unavailable |
 GOLF (Gene-Ortholog Location Finder) unavailable |
|
MOET (Multi-Ontology Enrichement) |
GOLF (Gene-Ortholog Location Finder) |
|
||||||||
Gene Ontology Annotations Click to see Annotation Detail View
Biological Process
Cellular Component
Molecular Function
Phenotype Annotations Click to see Annotation Detail View
Mammalian Phenotype
Gene-Chemical Interaction Annotations
Click to see Annotation Detail View
Gene Ontology Annotations
Click to see Annotation Detail View
Biological Process
|
|
Cellular Component
|
|
|
Phenotype Annotations
Click to see Annotation Detail View
Mammalian Phenotype
|
|
|
References
References - curated
| 1. | Barbieri AM, etal., Proc Natl Acad Sci U S A 1999 Sep 14;96(19):10729-34. |
| 2. | Brady KP, etal., Genome Res 1997 Nov;7(11):1085-93. |
| 3. | MGD data from the GO Consortium |
| 4. | MGD IEA |
| 5. | Neidhardt L, etal., Mech Dev 2000 Nov;98(1-2):77-94. |
| 6. | Okazaki Y, etal., Nature. 2002 Dec 5;420(6915):563-73. |
| 7. | RGD automated import pipeline |
| 8. | RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations |
| 9. | RGD automated import pipeline for gene-chemical interactions |
Additional References at PubMed
| PMID:8798419 | PMID:8889548 | PMID:10349636 | PMID:11042159 | PMID:11076861 | PMID:11217851 | PMID:11414704 | PMID:12067728 | PMID:12477932 | PMID:14610273 | PMID:14681479 | PMID:14691545 |
| PMID:15345710 | PMID:16141072 | PMID:16141073 | PMID:18171921 | PMID:18480165 | PMID:18848646 | PMID:18922900 | PMID:19004851 | PMID:19427292 | PMID:20223988 | PMID:21677750 | PMID:21873635 |
| PMID:22008794 | PMID:22227295 | PMID:22388892 | PMID:22464327 | PMID:23208928 | PMID:23271346 | PMID:23487314 | PMID:23558895 | PMID:23954751 | PMID:24086156 | PMID:24198274 | PMID:24316976 |
| PMID:24336287 | PMID:24652767 | PMID:24721909 | PMID:24735878 | PMID:24833705 | PMID:25340873 | PMID:25358790 | PMID:25480918 | PMID:25794708 | PMID:25826454 | PMID:25842978 | PMID:25921371 |
| PMID:26015543 | PMID:26073039 | PMID:26590425 | PMID:26651291 | PMID:26753643 | PMID:26837596 | PMID:26930384 | PMID:26935556 | PMID:27287810 | PMID:28094771 | PMID:28099467 | PMID:28494873 |
| PMID:28504705 | PMID:28814482 | PMID:29153838 | PMID:29249464 | PMID:29395868 | PMID:29643507 | PMID:30248341 | PMID:30323305 | PMID:30472156 | PMID:30578323 | PMID:30585163 | PMID:30886049 |
| PMID:30956133 | PMID:31059499 | PMID:31488717 | PMID:31564613 | PMID:31796338 | PMID:31813825 | PMID:32325033 | PMID:32515350 |
Genomics
